Mucosal immune response in BNT162b2 COVID-19 vaccine recipients.

ABSTRACT:

Background

Although the BNT162b2 COVID-19 vaccine is known to induce IgG neutralizing antibodies in serum protecting against COVID-19, it has not been studied in detail whether it could generate specific immunity at mucosal sites, which represent the primary route of entry of SARS-CoV-2.

Methods

Samples of serum and saliva of 60 BNT162b2-vaccinated healthcare workers were collected at baseline, two weeks after the first dose and two weeks after the second dose. Anti-S1-protein IgG and IgA total antibodies titres and the presence of neutralizing antibodies against the Receptor Binding Domain in both serum and saliva were measured by quantitative and by competitive ELISA, respectively.

Findings

Complete vaccination cycle generates a high serum IgG antibody titre as a si

SUBMITTER: Azzi L 

PROVIDER: S-EPMC8718969 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature